PPARβ/δ Agonist

Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ.

PPAR agonist 5 (compound 4b) is a potent PPAR agonist with EC₅₀ values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect.

Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research.

PPARα/δ agonist 2 (compound 14) is a potent PPARα and PPARδ agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/δ agonist 2 shows anti-inflammatory effects.

Pparδ agonist 1 is a PPAR-δ agonist, with an EC₅₀ of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.

Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC₅₀s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.

Fonadelpar is a PPARδ agonist, used in the research of neuroparalytic keratopathy.

Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1.

KD-3010 is a potent, orally active, and selective PPARδ agonist.

DN203316 (PPARδ agonist 11) is a potent, selective, orally active PPARδ agonist (EC₅₀ = 20 nM) with high selectivity over PPARα and PPARγ. DN203316 suppresses NF-κB-mediated inflammatory signaling, inhibits ferroptosis by upregulating xCT and GPX4, and attenuates STING-TBK1-IRF3-driven fibrogenic responses. DN203316 is useful for research on inflammatory disorders, metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis.